Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065320 | 0.83 | ACE (0.32) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL7066270 | 0.82 | ACE (0.32) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL7068838 | 0.81 | CYP1A2 (0.33) | ACELMNACYP3A4 | |
| SCHEMBL7065148 | 0.77 | USP30 (0.33) | USP30LMNANOTUM | |
| SCHEMBL7066181 | 0.77 | USP30 (0.36) | USP30NOTUM | |
| Hydrochloric Acid SCHEMBL7065326 | 0.77 | USP30 (0.33) | USP30NOTUM | |
| SCHEMBL7068740 | 0.76 | USP30 (0.33) | USP30NOTUM | |
| SCHEMBL6328311 | 0.75 | NR1H2 (0.34) | ACECYP3A4 | |
| SCHEMBL6334750 | 0.74 | HCRTR2 (0.31) | ACECYP3A4 | |
| SCHEMBL6608199 | 0.74 | HCRTR2 (0.31) | ACECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579886-B2 | Ionotropic glutamate receptors; 6-((4-carboxylic acid-1H-imidazol-1-yl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3 -carboxylic acid | ELI LILLY AND COMPANY | 2003-06-17 | — | — | US | disclosed |
| US-20030055081-A1 | Selective iglur5 receptor antagonists | ELI LILLY AND COMPANY | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055081-A1 | Selective iglur5 receptor antagonists | GRM5, GRIK5, GPR35 | USP30 2572/4885ACE 4406/4885MEN1 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.